TED R. MANNEN is Counsel to Epstein Becker Green and a Strategic Advisor for the firm's affiliate EBG Advisors, Inc. He has broad experience that spans government, industry, and professional services. While his work principally focuses on U.S. issues, he has also served as an advisor to industry in health policy-related talks with Germany, Japan, China, and other international governments and groups.

Mr. Mannen's experience includes serving as a lawyer and staff member in Congress; as General Counsel and as a senior policy, reimbursement, and public affairs executive at the international device and diagnostics trade group now known as the Advanced Medical Technology Association; and as Partner in two law firms and President of two law firm consulting affiliates.

Specifically, Mr. Mannen’s practice focuses on the following areas:

Health  Regulation & Intelligence

Mr. Mannen represents life sciences companies and trade associations on third-party payer regulatory issues and addresses these issues as part of due-diligence evaluations for investor organizations. His practice includes counseling clients on:

  • Medicare's proposed Part B drug payment model and other CMS Innovation Center initiatives
  • Comparative-effectiveness and technology assessment policies
  • Medicare Advantage benefits
  • Clinical diagnostic laboratory requirements
  • DME benefit-category qualification
  • U.S. Preventive Services Task Force recommendations
  • Medicare guidance on coverage with evidence development
  • Physician-payment and other Medicare provider rulemakings

His representative experience in this area includes:

  • Helping lead the device industry's work on coverage issues at the time Medicare introduced the modern regime for national decisions
  • Representing device and pharmaceutical industry clients on individual Medicare national, local, and regional coverage decisions
  • Assisting a client in successfully challenging Medicare's long-standing "Least Costly Alternative" policy for drugs 

In addition, Mr. Mannen developed an intelligence platform that evaluates government and other primary-information sources. He uses this capability to counsel clients and provide them monitoring services, with recent examples in such areas as:

  • State Medicaid requirements (for an international diagnostics company)
  • Accountable care organizations (for a life sciences trade association)
  • U.S. and international public and private medical policies and technology assessments (for an oncology-therapy company)
  • Average sales price methodology and reporting (for a pharmaceutical company)
  • State professional licensing developments (for a provider organization)

Mr. Mannen's intelligence platform supported his blog, HealthHombre, which The Wall Street Journal said read "more regulations, proposed rules, draft legislation and other stuff than is healthy for any person."

Health Policy & Legislation

For device, diagnostics, and pharmaceutical companies and trade associations, Mr. Mannen provides policy counseling and drafts and interprets legislation, amendments, specifications, and related materials. He has worked on health reform, Medicare, Medicaid, FDA, AHRQ, and other federal and state statutes and legislation. His representative experience in this area includes:

  • Developing concepts and drafting specifications for a new Medicare benefit category
  • Drafting a bill to create a Medicare reimbursement pathway for a new type of health care intervention
  • Preparing amendments to revise the methodology for calculating Medicare payments for certain institutional providers
  • Drafting amendments to create a Medicare Advantage demonstration project
  • Drafting bills and amendments to provide specialized requirements for individual types of care interventions

Mr. Mannen previously served as an attorney in the U.S. House's Office of the Legislative Counsel, where he drafted legislation for the Judiciary Committee. He was later an aide to U.S. Senator Adlai E. Stevenson (IL) on Banking Committee matters. Mr. Mannen has testified before Congressional committees on a number of life sciences issues. The American Bar Association Journal, in reference to Mr. Mannen's legislative drafting, described him as one of a "new breed of lawyer-lobbyist" that offers Congress "sophistication and expertise."

Market Access & Reimbursement

Mr. Mannen’s broad experience in this area includes:

  • Helping life sciences companies introduce their innovations into reimbursed markets, such as in Medicare and private health plans
  • Advising clients on how technology adoption is influenced by third-party insurer coverage, coding, and payment policies, as well as by emerging incentives designed to reward accountable, high-value care
  • Building and leading interdisciplinary teams to develop reimbursement assessments, strategies, and plans for companies in a variety of service categories, including home drug delivery; imaging; cardiovascular, orthopedic, and other implants; DME; laboratory tests; and screening, remote-monitoring, and other types of new medical technologies (many of which are commercialized in the United States as medical devices)

Mr. Mannen was selected as among the “100 Notable People in the Medical Device Industry” by Medical Device & Diagnostics Industry in June 2004.


  • Northwestern Pritzker School of Law (J.D., cum laude, 1975)
    • Notes and Comments Editor, Northwestern University Law Review
  • Southern Illinois University (B.A., with high honors, 1972)

Bar Admissions

  • District of Columbia